These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19497467)

  • 1. Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes.
    Hollander JE; Gibson CM; Pollack CV
    Am J Emerg Med; 2009 Jun; 27(5):595-606. PubMed ID: 19497467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
    JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.
    Coons JC; Battistone S
    Ann Pharmacother; 2008 Jul; 42(7):989-1001. PubMed ID: 18577763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes.
    Jennings LK; Saucedo JF
    Curr Opin Cardiol; 2008 Jul; 23(4):302-8. PubMed ID: 18520712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
    Kwa AT; Rogers JH
    J Interv Cardiol; 2008 Apr; 21(2):107-17. PubMed ID: 18248357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
    J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes and acute coronary syndromes.
    Roffi M; Eberli FR
    Best Pract Res Clin Endocrinol Metab; 2009 Jun; 23(3):305-16. PubMed ID: 19520305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
    Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial.
    Waksman R; Wolfram RM; Torguson RL; Okubagzi P; Xue Z; Suddath WO; Satler LF; Kent KM
    J Invasive Cardiol; 2006 Aug; 18(8):370-5. PubMed ID: 16877786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
    Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
    J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
    Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
    Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.
    Chan MY; Mahaffey KW; Sun LJ; Pieper KS; White HD; Aylward PE; Ferguson JJ; Califf RM; Roe MT
    JACC Cardiovasc Interv; 2008 Aug; 1(4):369-78. PubMed ID: 19463332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
    Cohen M; Hoekstra J; Giugliano R; Granger CB; Gurbel PA; Hollander JE; Manoukian SV; Pollack CV; Saucedo JF
    J Interv Cardiol; 2008 Aug; 21(4):283-99. PubMed ID: 18754964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gp IIb/IIIa receptor antagonists in acute coronary syndromes with no ST elevation].
    Decalf V; Sabbah L; Lafont A; Danchin N; Durand E
    Arch Mal Coeur Vaiss; 2007 Dec; 100(12):1006-12. PubMed ID: 18223514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
    Feldman DN; Wong SC; Bergman G; Minutello RM
    J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy.
    Goto K; Lansky AJ; Fahy M; Cristea E; Feit F; Ohman EM; White HD; Alexander KP; Bertrand ME; Desmet W; Hamon M; Mehran R; Stone GW
    Circulation; 2010 Feb; 121(7):853-62. PubMed ID: 20142447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimizing antithrombotic therapy in non-ST-elevation acute coronary syndrome].
    Ortigosa J
    Rev Esp Cardiol; 2007 Oct; 60 Suppl 3():31-6. PubMed ID: 18093492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: risk stratification and treatment strategies.
    Lefebvre CW; Hoekstra J
    Hosp Pract (1995); 2010 Apr; 38(2):40-9. PubMed ID: 20469612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.